Sparreboom, A.

patient cancer irinotecan pharmacokinetic study plasma paclitaxel concentration treatment sn -38 level cisplatin effect clearance -38 transporter analysis cpt -11 imatinib administration phase toxicity sample infusion docetaxel -11 value activity variant blood tumor metabolite table grade sparreboom genotype oncol cyp 3a transport result expression diarrhea dosing polymorphism exposure allele group metabolism pharmacol verweij protein research sn -38g function parameter neutropenia cycle cancer patients range uptake topotecan agent number inhibitor disposition variability association course model erythromycin midazolam ratio dose level verweij j response lactone carnitine r 101933 phase i ugt 1a